Q-omics provides the consensus-scored ARHGDIB profile across patient tissues and cancer cell-line models. ARHGDIB expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, ARHGDIB is differentially expressed in 12, with the highest sampling consensus in KIRC. Additionally, ARHGDIB protein abundance shows 32,686 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight HNSC, KIRC, and LSCC as cancer lineages where ARHGDIB shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ARHGDIB — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ARHGDIB survival associations across molecular data types. ARHGDIB RNA expression shows survival associations in the most cancer types (23), followed by mutation status (3) and mass-spec protein abundance (8). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ARHGDIB RNA expression–survival associations across cancer types. High ARHGDIB expression shows unfavorable associations in LGG, but favorable associations in HNSC, BLCA, SKCM, THCA and CESC. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for ARHGDIB RNA expression.
This table summarizes ARHGDIB tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 8. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for ARHGDIB. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ARHGDIB shows lower tumor expression in KICH and LUSC and higher tumor expression in KIRC, THCA, STAD and BRCA. The KIRC box plot shows higher ARHGDIB RNA expression in tumor versus normal tissue (log2 FC = +1.832, t-test p < 0.001).
This table shows molecular features associated with ARHGDIB in patient tissues and cancer cell lines. In patient samples, ARHGDIB shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, ARHGDIB RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in OVARY and BLOOD_Lymphoma.
